<DOC>
	<DOCNO>NCT02795065</DOCNO>
	<brief_summary>The purpose study compare two type low-molecular-weight heparin , enoxaparin bemiparin , regard efficacy safety venous thromboembolism prevention among intensive care unit patient .</brief_summary>
	<brief_title>Bemiparin Versus Enoxaparin Prevention Venous Thromboembolism Among ICU Patients</brief_title>
	<detailed_description>A prospective randomize trial compare thromboprophylaxis use bemiparin enoxaparin critically ill patient ICU . The study include one hundred bedridden patient intensive care unit high risk develop venous thromboembolism require long term anticoagulation Patients divide two group one consist 50 patient . One group receive bemiparin 3500 IU subcutaneous daily group receive enoxaparin 40 mg subcutaneous daily prophylaxis thromboembolism . Patients follow 60 day development deep venous thrombosis , pulmonary embolism complication relate injected anticoagulant .</detailed_description>
	<mesh_term>Thromboembolism</mesh_term>
	<mesh_term>Venous Thromboembolism</mesh_term>
	<mesh_term>Heparin , Low-Molecular-Weight</mesh_term>
	<criteria>Sepsis , stroke , major burn , respiratory failure , traumatic brain injury , malignancy post arrest intubate mechanically ventilate continuous IV sedation Hypersensitivity low molecular weight heparin , hypercoagulability , congenital acquire bleed disorder , prolongation activate partial thromboplastin time prothrombin time 20 % compare normal value ; thrombocytopenia ( platelet count &lt; 100,000/mm3 ) ; macroscopic hematuria ; uncontrolled hypertension [ systolic blood pressure &gt; 200 mmHg ; diastolic blood pressure &gt; 100 mmHg ] ; impaired kidney function : serum creatinine &gt; 2.0 mg/ dL bleed gastrointestinal ulcer .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>